Status:
COMPLETED
Adenocarcinoma of the Uterine Cervix and HPV
Lead Sponsor:
Università Politecnica delle Marche
Conditions:
Adenocarcinoma of the Uterine Cervix
Eligibility:
FEMALE
25-80 years
Brief Summary
The present study will mainly aim to review and characterize the pathologic features, treatment options, and follow-up outcomes of women with in situ/microinvasive adenocarcinoma of the uterine cervix...
Detailed Description
The incidence of cervical cancer in developed countries declined considerably in the last few decades. This has been possible for efficient screening programs to which HPV vaccines have been added ove...
Eligibility Criteria
Inclusion
- Women with in-situ or microinvasive (stage 1A) adenocarcinoma of the uterine cervix undergoing conization or hysterectomy, between January 2012 and December 2016.
- Women with HPV testing within 2 months before conization.
- Women should be diagnosed and managed by the corresponding center.
- Patients with adequate clinical and pathological data.
Exclusion
- Women with previous cervical treatments.
- Women with immunological disease (e.g. HIV).
- Unavailable HPV testing before surgery.
- Women with inadequate follow-up.
Key Trial Info
Start Date :
June 30 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 20 2023
Estimated Enrollment :
148 Patients enrolled
Trial Details
Trial ID
NCT05267834
Start Date
June 30 2022
End Date
March 20 2023
Last Update
March 24 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Gynecology and Obsetrics
Ancona, Italy, 60123